Skip to main content
. 2024 Oct 2;7(10):e2436888. doi: 10.1001/jamanetworkopen.2024.36888

Table 1. Baseline Characteristics of Study Population.

Characteristics HN019 group (n = 112) Placebo group (n = 117)
Age, mean (SD), y 46.0 (10.2) 44.1(10.2)
Age group, No. (%)
≤45 y 54 (48.2) 66 (56.4)
>45 y 58 (51.8) 51 (43.6)
Sex, No. (%)
Female 97 (86.6) 97 (82.9)
Male 15 (13.4) 20 (17.1)
BMI
Mean (SD) 22.8 (2.6) 22.8 (2.4)
Range 18.5-29.7 18.7-28.9
Smoking status, No. (%)
Ever 1 (0.9) 2 (1.7)
Never 111 (99.1) 115 (98.3)
Stool frequency, mean (SD)
CSBM/wk 0.73 (0.98) 0.81 (1.03)
SBM/wk 2.53 (1.46) 2.51 (1.34)
BM/wk 2.57 (1.44) 2.54 (1.34)
Stool consistency, mean (SD) BSS scorea 3.2 (1.1) 3.1 (1.1)
Gut symptoms, mean (SD) VAS score, mmb
Abdominal pain 4.8 (7.5) 4.8 (8.8)
Degree of straining 49.3 (24.9) 51.0 (24.6)
Bloating 10.8 (15.1) 10.0 (12.2)
PAC-SYM, total scorec 0.8 (0.5) 0.8 (0.5)
PAC-QoL, total scorec 1.3 (0.6) 1.2 (0.6)
Use of rescue medication, No. (%)
Yes 5 (4.5) 5 (4.3)
No 107 (95.5) 112 (95.7)

Abbreviations: BMI, body mass index (calculated as the weight in kilograms divided by the height in meters squared); BM, bowel movement; BSS, Bristol Stool Scale; CSBM, complete spontaneous BM; PAC-QoL, Patient Assessment of Constipation–Quality of Life; PAC-SYM, Patient Assessment of Constipation–Symptoms; SBM, spontaneous BM; VAS, visual analogue scale.

a

Scores range from 1 (separate hard lumps) to 7 (watery), with 3 to 5 indicating optimal.

b

Scores range from 0 to 100 mm, with greater scores indicating more severe symptoms.

c

Scores range from 0 (absent) to 4 (severe).